PAD
MCID: PRP027
MIFTS: 72

Peripheral Vascular Disease (PAD)

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Peripheral Vascular Disease

MalaCards integrated aliases for Peripheral Vascular Disease:

Name: Peripheral Vascular Disease 41 12 15 38 17
Peripheral Arterial Disease 41 43 3 63 17
Arterial Occlusive Disease 41 12 15 17
Peripheral Vascular Diseases 55 44 72
Arterial Occlusive Diseases 55 72
Pad 41 3
Peripheral Occlusive Disease 41
Peripheral Arterial Diseases 72
Helicobacter Infections 72

Classifications:



External Ids:

Disease Ontology 12 DOID:341
ICD9CM 35 443.81
MeSH 44 D016491
SNOMED-CT 68 2929001
ICD10 33 I73.8 I73.9
UMLS 72 C0003838 C0031115 C0079487 more

Summaries for Peripheral Vascular Disease

MedlinePlus : 43 Peripheral arterial disease (PAD) happens when there is a narrowing of the blood vessels outside of your heart. The cause of PAD is atherosclerosis. This happens when plaque builds up on the walls of the arteries that supply blood to the arms and legs. Plaque is a substance made up of fat and cholesterol. It causes the arteries to narrow or become blocked. This can reduce or stop blood flow, usually to the legs. If severe enough, blocked blood flow can cause tissue death and can sometimes lead to amputation of the foot or leg. The main risk factor for PAD is smoking. Other risk factors include older age and diseases like diabetes, high blood cholesterol, high blood pressure, heart disease, and stroke. Many people who have PAD don't have any symptoms. If you have symptoms, they may include Pain, numbness, achiness, or heaviness in the leg muscles. This happens when walking or climbing stairs. Weak or absent pulses in the legs or feet Sores or wounds on the toes, feet, or legs that heal slowly, poorly, or not at all A pale or bluish color to the skin A lower temperature in one leg than the other leg Poor nail growth on the toes and decreased hair growth on the legs Erectile dysfunction, especially among men who have diabetes PAD can increase your risk of heart attack, stroke, and transient ischemic attack. Doctors diagnose PAD with a physical exam and heart and imaging tests. Treatments include lifestyle changes, medicines, and sometimes surgery. Lifestyle changes include dietary changes, exercise, and efforts to lower high cholesterol levels and high blood pressure. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Peripheral Vascular Disease, also known as peripheral arterial disease, is related to arteriosclerosis obliterans and grange syndrome, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Peripheral Vascular Disease is ALB (Albumin), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Lipoprotein metabolism. The drugs Ticlopidine and Nicotinamide have been mentioned in the context of this disorder. Affiliated tissues include Bone, heart and endothelial, and related phenotypes are Decreased free cholesterol and cardiovascular system

Disease Ontology : 12 A vascular disease that is characterized by obstruction of larger arteries not within the coronary, aortic arch vasculature, or brain.

CDC : 3 Peripheral Arterial Disease (PAD) in the Legs or lower extremities is the narrowing or blockage of the vessels that carry blood from the heart to the legs. It is primarily caused by the buildup of fatty plaque in the arteries, which is called atherosclerosis. PAD can occur in any blood vessel, but it is more common in the legs than the arms.

PubMed Health : 63 About peripheral arterial disease: Peripheral arterial disease (P.A.D.) is a disease in which plaque (plak) builds up in the arteries that carry blood to your head, organs, and limbs. Plaque is made up of fat, cholesterol, calcium, fibrous tissue, and other substances in the blood. When plaque builds up in the body's arteries, the condition is called atherosclerosis (ATH-er-o-skler-O-sis). Over time, plaque can harden and narrow the arteries. This limits the flow of oxygen-rich blood to your organs and other parts of your body. P.A.D. usually affects the arteries in the legs, but it also can affect the arteries that carry blood from your heart to your head, arms, kidneys, and stomach. This article focuses on P.A.D. that affects blood flow to the legs.

Related Diseases for Peripheral Vascular Disease

Diseases related to Peripheral Vascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 651)
# Related Disease Score Top Affiliating Genes
1 arteriosclerosis obliterans 32.7 VCAM1 SELP IL6
2 grange syndrome 31.9 VWF VCAM1 THBD SELP SELE PLAT
3 carotid stenosis 31.4 SELP CRP ACE
4 limb ischemia 31.1 VWF VEGFA IL6 ACE
5 generalized atherosclerosis 31.1 SELP CRP ACE
6 ischemia 31.1 VEGFA SELP PLAT ACE
7 chronic venous insufficiency 30.9 VCAM1 SELP PLAT
8 retinal vascular disease 30.8 VEGFA ALB ACE
9 sleep apnea 30.6 IL6 CRP ACE
10 hyperlipoproteinemia, type iii 30.6 LPA CETP APOB APOA1
11 microvascular complications of diabetes 5 30.6 VEGFA VCAM1 ALB ACE
12 polyarteritis nodosa 30.5 SELE IL6 CRP
13 systemic scleroderma 30.5 SELP SELE CRP ACE
14 branch retinal artery occlusion 30.4 SERPINC1 F3 F2
15 aortic valve disease 2 30.4 VWF CRP ACE
16 hypertriglyceridemia, familial 30.4 CETP APOB APOA1
17 heart valve disease 30.4 VWF CRP ACE
18 end stage renal failure 30.4 IL6 CRP APOB ALB ACE
19 rheumatic heart disease 30.3 VCAM1 IL6 ACE
20 intermittent claudication 30.3 VWF VEGFA SERPINC1 SELP IL6 F2
21 homocysteinemia 30.3 SERPINC1 F2 CRP ALB
22 pulmonary edema 30.2 F2 CRP ACE
23 uremia 30.2 VWF CRP ALB
24 aortic atherosclerosis 30.2 LPA CETP ACE
25 diabetes mellitus, insulin-dependent 30.2 IL6 APOB ALB ACE
26 leukodystrophy, hypomyelinating, 3 30.2 LPA APOB APOA1
27 angina pectoris 30.2 SERPINC1 PLAT IL6 CRP ACE
28 systolic heart failure 30.1 IL6 CRP ACE
29 nonarteritic anterior ischemic optic neuropathy 30.1 SERPINC1 F2 ACE
30 afibrinogenemia 30.1 VWF F3 F2
31 thrombophlebitis 30.0 SERPINC1 PLAT F2
32 hypersplenism 30.0 SERPINC1 F2 ALB
33 hemophilia 30.0 VWF F3 F2
34 respiratory failure 30.0 F3 CRP ALB ACE
35 kidney disease 30.0 LPA IL6 CRP ALB ACE
36 heparin-induced thrombocytopenia 30.0 SERPINC1 F3
37 sudden sensorineural hearing loss 30.0 IL6 F2
38 venous insufficiency 29.9 VWF VCAM1 SELP PLAT F2 CRP
39 peripheral artery disease 29.9 VEGFA VCAM1 SELP IL6 CRP APOB
40 leptospirosis 29.9 IL6 F2 CRP
41 coronary restenosis 29.9 SERPINC1 CETP ACE
42 retinal artery occlusion 29.9 VEGFA SERPINC1 IL6 F2 ACE
43 varicose veins 29.8 VWF VEGFA SERPINC1 F2
44 post-thrombotic syndrome 29.8 SERPINC1 IL6 F2
45 kawasaki disease 29.8 SELE IL6 CRP ALB
46 diabetic angiopathy 29.8 VWF THBD SELE
47 von willebrand's disease 29.7 VWF SELP F3 F2
48 vasculitis 29.7 VWF VCAM1 THBD SELE CRP
49 protein s deficiency 29.7 SERPINC1 F3 F2
50 subendocardial myocardial infarction 29.7 VCAM1 SERPINC1 SELE F2

Comorbidity relations with Peripheral Vascular Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 95)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Acute Vascular Insufficiency of Intestine Anxiety
Aortic Aneurysm Aortic Atherosclerosis
Aortic Valve Disease 1 Autonomic Nervous System Disease
Basilar Artery Insufficiency Benign Essential Hypertension
Benign Renovascular Hypertension Bleeding Disorder, Platelet-Type, 11
Bronchitis Bronchopneumonia
Buerger Disease Cardiac Arrest
Cardiogenic Shock Cerebral Atherosclerosis
Cerebrovascular Disease Chronic Intestinal Vascular Insufficiency
Chronic Pulmonary Heart Disease Chronic Ulcer of Skin
Decubitus Ulcer Deficiency Anemia
Dermatomycosis Diabetes Mellitus, Noninsulin-Dependent
Diabetic Peripheral Angiopathy Diabetic Polyneuropathy
Dressler's Syndrome Dysthymic Disorder
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Gas Gangrene
Generalized Atherosclerosis Gout
Heart Disease Hyperlipoproteinemia, Type Iv
Hyperlipoproteinemia, Type V Hypertension, Essential
Hypertensive Encephalopathy Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome
Hypoglycemia Hypoglycemic Coma
Hypothyroidism Intermediate Coronary Syndrome

Graphical network of the top 20 diseases related to Peripheral Vascular Disease:



Diseases related to Peripheral Vascular Disease

Symptoms & Phenotypes for Peripheral Vascular Disease

UMLS symptoms related to Peripheral Vascular Disease:


angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Peripheral Vascular Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.02 APOA1 APOB CETP LPA SELP

MGI Mouse Phenotypes related to Peripheral Vascular Disease:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.39 ACE APOA1 APOB CRP F2 F3
2 homeostasis/metabolism MP:0005376 10.39 ACE ALB APOA1 APOB CRP F2
3 hematopoietic system MP:0005397 10.29 ACE F2 F3 IL6 PF4 PLAT
4 immune system MP:0005387 10.28 ACE APOB CRP F2 F3 IL6
5 cellular MP:0005384 10.27 ALB APOA1 APOB F3 IL6 PLAT
6 mortality/aging MP:0010768 10.17 ACE ALB APOB F2 F3 IL6
7 liver/biliary system MP:0005370 10.07 ACE ALB APOA1 APOB IL6 SELE
8 integument MP:0010771 10.06 APOA1 F2 F3 IL6 PLAT SELE
9 reproductive system MP:0005389 9.81 ACE APOB F2 IL6 PLAT SERPINC1
10 renal/urinary system MP:0005367 9.8 ACE ALB IL6 SELP SERPINC1 THBD
11 respiratory system MP:0005388 9.56 F2 F3 IL6 PLAT SELE SELP
12 vision/eye MP:0005391 9.23 APOB F3 IL6 PLAT SELE SELP

Drugs & Therapeutics for Peripheral Vascular Disease

PubMed Health treatment related to Peripheral Vascular Disease: 63

Treatments for peripheral arterial disease (P.A.D.) include lifestyle changes, medicines, and surgery or procedures. The overall goals of treating P.A.D. include reducing symptoms, improving quality of life, and preventing complications. Treatment is based on your signs and symptoms, risk factors, and results from a physical exam and tests. Treatment may slow or stop disease progress and reduce the risk of complications. Without treatment, P.A.D. can cause sores or gangrene (tissue death). In extreme cases, it may be necessary to remove part of the leg or foot (amputation).

Drugs for Peripheral Vascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 610)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ticlopidine Approved Phase 4 55142-85-3 5472
2
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
3
Acetaminophen Approved Phase 4 103-90-2 1983
4
Piperacillin Approved Phase 4 66258-76-2 43672
5
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
6
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
7
Tazobactam Approved Phase 4 89786-04-9 123630
8
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
9
Aztreonam Approved Phase 4 78110-38-0 5742832 5362041
10
Capsaicin Approved Phase 4 404-86-4 1548943
11
Dinoprostone Approved Phase 4 363-24-6 5280360
12
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
13
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
14
Menthol Approved Phase 4 2216-51-5 16666
15
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
16
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
17
Sodium citrate Approved, Investigational Phase 4 68-04-2
18
Testosterone enanthate Approved Phase 4 315-37-7 9416
19
Methyltestosterone Approved Phase 4 58-18-4 6010
20
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
21
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
22
Dalteparin Approved Phase 4 9005-49-6
23
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
24
Ezetimibe Approved Phase 4 163222-33-1 150311
25
Clonidine Approved Phase 4 4205-90-7 2803
26
Morphine Approved, Investigational Phase 4 57-27-2 5288826
27
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
28
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
29
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
30
Dobutamine Approved Phase 4 34368-04-2 36811
31
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
32
Racepinephrine Approved Phase 4 329-65-7 838
33
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
34
Defibrotide Approved, Investigational Phase 4 83712-60-1
35
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
36
Pantoprazole Approved Phase 4 102625-70-7 4679
37
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
38
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
39
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
40
Epoprostenol Approved Phase 4 35121-78-9, 61849-14-7 5282411 5280427
41
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
42
Titanium dioxide Approved Phase 4 13463-67-7
43
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
44
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
45
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
46
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
47
Coal tar Approved Phase 4 8007-45-2
48
Norepinephrine Approved Phase 4 51-41-2 439260
49
Allantoin Approved Phase 4 97-59-6 204
50
Triflusal Approved, Investigational Phase 4 322-79-2

Interventional clinical trials:

(show top 50) (show all 1842)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Therapeutic Used Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease Unknown status NCT01711333 Phase 4 Pletaal SR capsule
2 Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS) Unknown status NCT01083394 Phase 4
3 SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial Unknown status NCT02959606 Phase 4 Sarpogrelate SR 300mg;Clopidogrel
4 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA) Unknown status NCT02033135 Phase 4
5 Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease Unknown status NCT00986752 Phase 4
6 A Randomized Controlled Trial Comparing Usual Care With a Multifactorial Intensified Intervention on Cardiovascular Risk Factors in Subjects With Arterial Peripheral Disease With and Without Diabetes. The Taulí Intervention Program (TIP). Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
7 Evaluation of Closed Incision Negative Pressure Device (Prevena) to Prevent Vascular Wound Complications Unknown status NCT02581904 Phase 4
8 Tailored Strategy for Residual Platelet Activity In Advanced Peripheral Artery Disease: New Optimal Management. Unknown status NCT01627431 Phase 4 Acetylsalicylic acid;Clopidogrel
9 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROLTM Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP-2 Trial) Unknown status NCT01653600 Phase 4
10 Comparison Efficacy of 14-day Triple Therapy Between Clarithromycin and Levofloxacin on the Eradication of Helicobacter Pylori in Syrian Population Unknown status NCT02693574 Phase 4 Clarithromycin;Levofloxacin
11 The Prism Trial: A Retrospective Case Review of Technical Success Using the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery Unknown status NCT02085551 Phase 4
12 The Study to Compare the Treatment of Stent and Prothesis Bypass in SFA Occlusions Unknown status NCT01147419 Phase 4
13 Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole Unknown status NCT02552641 Phase 4 Esomeprazole;Amoxicillin;Clarythromycin
14 Paclitaxel-eluting Balloon Angioplasty With Provisional Use of Nitinol Stent Versus Systematic Implantation of Paclitaxel-eluting Stent for the Treatment of Femoropopliteal de Novo Lesions Unknown status NCT01969630 Phase 4
15 Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix Unknown status NCT02279784 Phase 4
16 Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Unknown status NCT02563535 Phase 4
17 Study of the OmniWave Endovascular System in Subjects With Lower and Upper Extremity Deep Vein Thrombosis - SONIC I Study Unknown status NCT00640731 Phase 4
18 Estimation de la capacité Fonctionnelle à la Marche Par Questionnaire Clinique Chez Les Patients adressés Pour Bilan artériel Des Membres inférieurs Unknown status NCT01424020 Phase 4
19 A Randomized, Double-blind, Placebo-controlled Study of the Usefulness of the Probiotic 'Lactobacillus Reuteri' in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice Unknown status NCT03150394 Phase 4
20 Phase 4 Study of Helicobacter Pylori Eradication Therapy Unknown status NCT00990405 Phase 4 Lansoprzole+Amoxicillin+Clarithromycin
21 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
22 Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy of Treatment of Helicobacter Pylori Infection in Korea Unknown status NCT02108184 Phase 4 Sequential therapy 10 days;Sequential therapy 14 days;Concomitant therapy 10 days;Concomitant therapy 14 days
23 Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment Unknown status NCT02988089 Phase 4 Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
24 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
25 Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial Unknown status NCT02635191 Phase 4 Tailored Group;Standard group
26 Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT01906879 Phase 4 triple, quadruple, non-bismuth quadruple therapy
27 Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy Unknown status NCT01265069 Phase 4 high dose dual therapy;concomitant therapy
28 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
29 EVALUATION OF THE RELATIONSHIP BETWEEN EFFERVESCENT PARACETAMOL AND BLOOD PRESSURE. CLINICAL TRIAL. Unknown status NCT02514538 Phase 4 Non- effervescent Paracetamol kern;Effervescent paracetamol termalgin
30 Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial Unknown status NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
31 Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections Unknown status NCT01566643 Phase 4 RA5-RACM7;RA3-RACM7;RA7-RACM7
32 Peripheral Artery Disease in Patients on Maintenance Hemodialysis: Risk Factors and the Effect of FIR Therapy Unknown status NCT01095549 Phase 4
33 A Randomized, Controlled Study to Investigate the Efficacy and Safety of a Topical Gentamicin-Collagen Sponge in Combination With Systemic Antibiotic Therapy in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Unknown status NCT01951768 Phase 4 Garamycin Sponge (Gentamicin-Collagen sponge);Systemic Antibiotic
34 The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease Unknown status NCT01138254 Phase 4
35 Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
36 Helicobacter Pylori Eradication Using a Bismuth Quadruple Therapy Among Asymptomatically Infected Adults in El Paso, Texas: A Pilot Study. Unknown status NCT01335334 Phase 4 bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole
37 Perioperative Visual Therapy May Help Prevent Phantom Limb Pain Unknown status NCT02383979 Phase 4
38 Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
39 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
40 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
41 Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients Unknown status NCT01128101 Phase 4 Spironolactone
42 Endovascular Treatment Versus Optimal Medical Treatment of Atherosclerotic Renal Artery for Preserving Renal Function of the Ischemic Kidney. Unknown status NCT01208714 Phase 4 Optimal medical therapy
43 The Effect of High Dose Arginine Infusion on Hemodynamic and Peripheral Microcirculation: a Randomized, Controlled Clinical Trial in Patients Receiving Peripheral Vascular Surgery Completed NCT01682889 Phase 4
44 A Phase IV Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral Digital Subtraction Angiography (DSA) Completed NCT00740207 Phase 4 VISIPAQUE 270;Isovue 250
45 The Jetstream G2 System Post-Market Peripheral Vascular IVUS Study Completed NCT00911417 Phase 4
46 Jetstream NAVITUS™ System Endovascular Therapy Post-market Registry (JET) Completed NCT01436435 Phase 4
47 A Clinical Study of Gadoteric Acid in Non-Coronary Magnetic Resonance (MR) Completed NCT00447889 Phase 4 gadoteric acid
48 Multinational, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Critical Limb Ischemia (Fontaine Stage IV) Completed NCT00596752 Phase 4 Alprostadil
49 A Phase IV Multi-Center Study to Compare ISOVUE -250 and VISIPAQUE 270 for Motion Artifact and Pain in Peripheral Digital Subtraction Angiography (DSA) Completed NCT01075217 Phase 4 iopamidol;iodixanol
50 Femoral Artery In-Stent Restenosis (FAIR) Trial Completed NCT01305070 Phase 4

Search NIH Clinical Center for Peripheral Vascular Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


alteplase
BISMUTH HYDROXIDE
BISMUTH RESORCIN COMPOUND
bismuth subcarbonate
BISMUTH SUBCARBONATE PWDR
bismuth subcitrate
bismuth subgallate
BISMUTH SUBIODIDE
bismuth subnitrate
BISMUTH SUBNITRATE PWDR
bismuth subsalicylate
BISMUTH-FORMIC-IODIDE
cilostazol
Cimetidine
Cimetidine Hydrochloride
Cyclandelate
Epoprostenol
Epoprostenol Sodium
Esomeprazole
Esomeprazole magnesium
esomeprazole sodium
Esomeprazole Strontium
Famotidine
lansoprazole
Metronidazole
Metronidazole Hydrochloride
METRONIDAZOLE PWDR
Niacin
Niacinamide
Nizatidine
Omeprazole
Omeprazole 2 MG/ML Oral Suspension
Omeprazole magnesium
pantoprazole
Pantoprazole sodium
Papaverine
Papaverine Hydrochloride
rabeprazole
Streptokinase
Tolazoline
Tolazoline Hydrochloride

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Peripheral Vascular Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Peripheral Vascular Disease:
ACY001, bone marrow-derived hematopoietic stem cells for coronary artery occlusions
ALD-301, bone marrow-derived cells for critical limb ischemia
Alecmestencel-T, mesenchymal stem cells for ischemic diseases
ALO212, umbilical cord blood-derived stem cell concentrate for vascular diseases
Autologus endothelial progenitor cells for the treatment of critical limb ischemia
Autologus hematopoeitic stem cells for the treatment of critical limb ischemia
Bone marrow-derived CD133+ or nucleated cells for peripheral artery disease
Bone marrow-derived mononuclear cells for peripheral vascular disease
Bone marrow-derived mononuclear stem cells for treatment of critical limb ischemia
Endothelial progenitor cells for peripheral artery disease
Enriched bone marrow-derived progenitor cells for ischemic diseases
MultiGeneAngio, genetically modified endothelial and smooth muscle cells for vascular disease
MultiStem, bone marrow-derived cells for peripheral vascular disease
Peripheral blood-derived hematopoietic stem cells for leg gangrene
TGI PVG, adipose-derived stem cell-coated vascular graft for peripheral vascular disease
VASCUGEL, aortic endothelial cells for vascular injury and disease
Embryonic/Adult Cultured Cells Related to Peripheral Vascular Disease:
Bone marrow-derived CD133+ stem cells
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905 19324906
Bone marrow-derived mesenchymal stem cells (family)
Cord blood-derived hematopoietic stem cell PMIDs: 19558779
Peripheral blood-derived endothelial cells PMIDs: 18388019 19448678
Peripheral blood-derived hematopoietic stem cells PMIDs: 18388019
Bone marrow-derived mononuclear cells (family)
Bone marrow-derived mononuclear cells
Bone marrow-derived mononuclear cells
Peripheral blood-derived endothelial progenitor cells PMIDs: 10725398
Bone marrow-derived progenitor cells
MultiGeneAngio, transduced vein-derived endothelial cells
Genetically modified vein-derived endothelial cells
Genetically modified vein-derived smooth muscle
MultiGeneAngio, transduced vein-derived smooth muscle cells
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 21175285 23307829
Peripheral blood-derived hematopoietic stem cells
Adipose-derived stromal cells PMIDs: 8207032 23350681
Aortic endothelial cells cultured in matrix PMIDs: 7667257
Aortic endothelial cells cultured in matrix (VASCUGEL) PMIDs: 7667257

Cochrane evidence based reviews: peripheral vascular diseases

Genetic Tests for Peripheral Vascular Disease

Anatomical Context for Peripheral Vascular Disease

MalaCards organs/tissues related to Peripheral Vascular Disease:

41
Heart, Endothelial, Testes, Kidney, Bone, Skin, Bone Marrow
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Peripheral Vascular Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Peripheral Vascular Disease

Articles related to Peripheral Vascular Disease:

(show top 50) (show all 16392)
# Title Authors PMID Year
1
Paclitaxel-coated balloons and stents for the treatment of peripheral artery disease: proceedings from the Cardiovascular Research Technologies (CRT) 2019 Town Hall. 17
31322122 2019
2
Impact of Arterial Procedures on Coagulation and Fibrinolysis - A Pilot Study. 17
31310472 2019
3
Systemic Sclerosis: A Clinical Analysis of Foot Findings in 52 Cases. 17
31331136 2018
4
Trends in patient characteristics and first-year medical costs of older incident hemodialysis patients, 1995-2005. 9 38
20116913 2010
5
Predicting six-month mortality for patients who are on maintenance hemodialysis. 9 38
19965531 2010
6
Peritoneal protein clearance and not peritoneal membrane transport status predicts survival in a contemporary cohort of peritoneal dialysis patients. 9 38
19478100 2009
7
Exercise and limitations in physical activity levels among new dialysis patients in the United States: an epidemiologic study. 9 38
19041586 2008
8
Effects of peripheral vascular intervention on ischemia-modified albumin. 9 38
17627187 2007
9
ACE gene polymorphism in peripheral vascular disease. 9 38
17611909 2007
10
Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most. 9 38
17556876 2007
11
Evaluation of a protocol for prevention of facility-acquired heel pressure ulcers. 9 38
17413835 2007
12
A perspective on telmisartan and cardiovascular risk. 9 38
17938615 2007
13
Peripheral arterial disease: a review of disease awareness and management. 9 38
17296541 2006
14
Optimal medical management of peripheral arterial disease. 9 38
16959725 2006
15
The impact of topical mupirocin on peritoneal dialysis infection in Singapore General Hospital. 9 38
16046516 2005
16
The impact of topical mupirocin on peritoneal dialysis infection rates in Singapore General Hospital. 9 38
15855200 2005
17
A high calcium-phosphate product is associated with high C-reactive protein concentrations in hemodialysis patients. 9 38
16103720 2005
18
Validation of the Kidney Disease Quality of Life (KDQOL) cognitive function subscale. 9 38
15569327 2004
19
Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. 9 38
15265817 2004
20
[The metabolic syndrome in patients with type 1 diabetes mellitus. Associations with cardiovascular risk factors and cardiovascular morbidity]. 9 38
15340731 2004
21
[Diabetes and atherosclerotic coronary damage in uremia]. 9 38
15356846 2004
22
Relationship between diabetes mellitus and degree of coronary artery disease in uraemic patients investigated with coronary angiography. 9 38
12703884 2003
23
Hypertension as a determinant of survival for patients treated with home dialysis. 9 38
12427157 2002
24
Lack of association between angiotensin-converting enzyme gene polymorphism and peripheral vascular disease in type 2 diabetic patients in Taiwan. 9 38
12419932 2002
25
Association of serum albumin and atherosclerosis in chronic hemodialysis patients. 9 38
12324906 2002
26
Minimally invasive vein harvesting significantly reduces pain and wound morbidity. 9 38
12204728 2002
27
Smoking causes a dose-dependent increase in granulocyte-bound L-selectin. 9 38
12165281 2002
28
Pre-dialysis clinic attendance improves quality of life among hemodialysis patients. 9 38
11934351 2002
29
The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin. 9 38
11941273 2002
30
From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. 9 38
11835907 2002
31
Determinants of physical performance in ambulatory patients on hemodialysis. 9 38
11576377 2001
32
Cross-sectional and longitudinal predictors of serum albumin in hemodialysis patients. 9 38
11044233 2000
33
Prostaglandin E1-therapy reduces circulating adhesion molecules (ICAM-1, E-selectin, VCAM-1) in peripheral vascular disease. 9 38
11037715 2000
34
Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. 9 38
10933355 2000
35
The anti-ischemic potential of angiotensin-converting enzyme inhibition: insights from the heart outcomes prevention evaluation trial. 9 38
10894450 2000
36
The effect of small solute clearances on survival of anuric peritoneal dialysis patients. 9 38
10809241 2000
37
Net mass transfer of plasma cholesteryl esters and lipid transfer proteins in normolipidemic patients with peripheral vascular disease. 9 38
10582542 1999
38
A randomized trial of endoscopic versus open saphenous vein harvest in coronary bypass surgery. 9 38
10543556 1999
39
Transvascular and urinary leakage of albumin in atherosclerotic and hypertensive men. 9 38
9719061 1998
40
Total body nitrogen predicts long-term mortality in haemodialysis patients--a single-centre experience. 9 38
9681720 1998
41
[Current pharmaco-therapeutic strategies in the treatment of arterial hypertension]. 9 38
9813738 1998
42
Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. 9 38
9241735 1997
43
Urinary albumin excretion rate and cardiovascular disease in Spaniard type 2 diabetic patients. 9 38
9229197 1997
44
Cell adhesion molecules and insulin-like growth factor-1 in vascular disease. 9 38
9152314 1997
45
von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? 9 38
9205537 1997
46
Lipid profile and peripheral vascular disease in arseniasis-hyperendemic villages in Taiwan. 9 38
9112880 1997
47
Incidence of distal symmetric (sensory) neuropathy in NIDDM. The San Luis Valley Diabetes Study. 9 38
9051381 1997
48
Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. 9 38
8960840 1996
49
Soluble P selectin in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease and its risk factors. 9 38
9034560 1996
50
A model that predicts morbidity and mortality after coronary artery bypass graft surgery. 9 38
8890808 1996

Variations for Peripheral Vascular Disease

Expression for Peripheral Vascular Disease

Search GEO for disease gene expression data for Peripheral Vascular Disease.

Pathways for Peripheral Vascular Disease

Pathways related to Peripheral Vascular Disease according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.55 VWF VEGFA THBD SERPINC1 SELP SELE
2
Show member pathways
12.47 LPA CETP APOB APOA1 ALB
3
Show member pathways
12.14 PLAT IL6 F2 CRP APOB APOA1
4
Show member pathways
12.13 THBD SELP SELE PF4 F2 APOB
5 12.02 VEGFA VCAM1 THBD SELE PLAT
6 11.99 VWF THBD SERPINC1 PLAT F3 F2
7 11.95 VEGFA VCAM1 IL6 ALB
8
Show member pathways
11.88 LPA CETP APOB APOA1
9
Show member pathways
11.7 VWF THBD SERPINC1 PLAT PF4 F3
10 11.63 VEGFA VCAM1 THBD SELE IL6 F3
11
Show member pathways
11.6 VEGFA VCAM1 SELE IL6
12 11.45 VCAM1 SELP SELE IL6
13 11.4 SELP PLAT LPA IL6 APOB
14 11.37 F2 APOA1 ALB
15 11.3 VCAM1 SELE IL6 APOA1

GO Terms for Peripheral Vascular Disease

Cellular components related to Peripheral Vascular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.91 VEGFA VCAM1 THBD PLAT F3 APOA1
2 extracellular region GO:0005576 9.86 VWF VEGFA SERPINC1 PPBP PLAT PF4
3 endoplasmic reticulum lumen GO:0005788 9.8 SERPINC1 IL6 F2 APOB APOA1 ALB
4 collagen-containing extracellular matrix GO:0062023 9.73 VWF SERPINC1 PLAT PF4 F3 APOA1
5 blood microparticle GO:0072562 9.71 SERPINC1 F2 APOA1 ALB
6 extracellular space GO:0005615 9.58 VEGFA VCAM1 THBD SERPINC1 SELP SELE
7 platelet alpha granule lumen GO:0031093 9.55 VWF VEGFA PPBP PF4 ALB
8 chylomicron GO:0042627 9.48 APOB APOA1
9 intermediate-density lipoprotein particle GO:0034363 9.46 APOB APOA1
10 extracellular exosome GO:0070062 10.07 VWF VCAM1 SERPINC1 PLAT F2 CETP

Biological processes related to Peripheral Vascular Disease according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 VEGFA PF4 IL6 CRP APOB
2 post-translational protein modification GO:0043687 9.97 SERPINC1 IL6 APOB APOA1 ALB
3 cytokine-mediated signaling pathway GO:0019221 9.92 VEGFA VCAM1 PF4 IL6 F3
4 inflammatory response GO:0006954 9.91 SELP SELE PPBP PF4 IL6 CRP
5 cholesterol homeostasis GO:0042632 9.85 CETP APOB APOA1
6 lipid transport GO:0006869 9.85 LPA CETP APOB APOA1
7 cholesterol metabolic process GO:0008203 9.83 CETP APOB APOA1
8 response to nutrient GO:0007584 9.82 VCAM1 SERPINC1 APOA1
9 platelet activation GO:0030168 9.81 VWF PF4 IL6 F2
10 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.79 PPBP PF4 F2
11 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.75 VCAM1 SELP SELE
12 cellular protein metabolic process GO:0044267 9.73 SERPINC1 IL6 F2 APOB APOA1 ALB
13 response to lipopolysaccharide GO:0032496 9.72 VCAM1 THBD SELP SELE APOB
14 acute-phase response GO:0006953 9.71 IL6 F2 CRP
15 regulation of blood coagulation GO:0030193 9.67 SERPINC1 F2
16 leukocyte cell-cell adhesion GO:0007159 9.67 VCAM1 SELP SELE
17 positive regulation of leukocyte migration GO:0002687 9.66 VEGFA SELP
18 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.66 CRP CETP
19 positive regulation of positive chemotaxis GO:0050927 9.65 VEGFA F3
20 cholesterol transport GO:0030301 9.65 CETP APOB APOA1
21 phospholipid homeostasis GO:0055091 9.64 CETP APOA1
22 negative regulation of fibrinolysis GO:0051918 9.64 THBD F2
23 chylomicron assembly GO:0034378 9.63 APOB APOA1
24 very-low-density lipoprotein particle remodeling GO:0034372 9.63 CETP APOA1
25 leukocyte tethering or rolling GO:0050901 9.63 VCAM1 SELP SELE
26 blood coagulation GO:0007596 9.63 VWF THBD SERPINC1 PLAT F3 F2
27 negative regulation of platelet activation GO:0010544 9.62 THBD F2
28 negative regulation of lipid storage GO:0010888 9.62 IL6 CRP
29 neutrophil mediated immunity GO:0002446 9.61 IL6 ACE
30 chylomicron remodeling GO:0034371 9.6 APOB APOA1
31 lipoprotein biosyntheti